Brief: Regulus Therapeutics Announces Completion Of Enrollment In Second Cohort Of Phase 1B Trial Of Rgls8429 In A Kidney Disease Study

Regulus Therapeutics

13/09/2023 13:59

Sept 13 (Reuters) - Regulus Therapeutics Inc  RGLS.O :
    * REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
SECOND COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL
TRIAL OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL
DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    * REGULUS THERAPEUTICS- EXPECTS TO BEGIN DOSING THIRD COHORT
FOLLOWING A REVIEW OF ALL AVAILABLE COHORT 2 SAFETY DATA, WHICH
IS PLANNED FOR OCTOBER 2023

Source text for Eikon:  ID:nPn21ZVVfa 
Further company coverage:  RGLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))